An FDA Commissioner for the 21st Century
The FDA faces challenges including a speed-versus-safety trade-off, the need to work well with industry, pressure on drug pricing, and tough policy choices under the 21st Century Cures Act. Commissioner-nominee Scott Gottlieb seems well qualified to address them. President Donald Trump has named Sco...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2017-04, Vol.376 (15), p.e31-e30 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e30 |
|---|---|
| container_issue | 15 |
| container_start_page | e31 |
| container_title | The New England journal of medicine |
| container_volume | 376 |
| creator | Chandra, Amitabh Sachs, Rachel E |
| description | The FDA faces challenges including a speed-versus-safety trade-off, the need to work well with industry, pressure on drug pricing, and tough policy choices under the 21st Century Cures Act. Commissioner-nominee Scott Gottlieb seems well qualified to address them.
President Donald Trump has named Scott Gottlieb as his nominee to be the next commissioner of the Food and Drug Administration (FDA). As compared with some of the other people whose names were floated publicly for the position, Gottlieb is a traditional choice, a physician who served in a deputy commissioner role under President George W. Bush. Observers who opposed Commissioner Robert Califf because of his relationships with drug companies will surely express concern about Gottlieb’s consulting in this area. But he would have been on the short list for any Republican administration. If confirmed, Gottlieb would take the helm . . . |
| doi_str_mv | 10.1056/NEJMp1703979 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1887050310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321693071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-d3ae3faaf661b6b229f72b53055850b7ef8d2a8930fd2e7feed2fb9776794cca3</originalsourceid><addsrcrecordid>eNpt0D1PwzAQBmALgWgpbMwoEgwdCJztOI7HKrR8qMACs-UkZ9GqSYqdDP33GFoQQtxywz16dXoJOaVwRUGk10_Th8c1lcCVVHtkSAXncZJAuk-GACyLE6n4gBx5v4QwNFGHZMCyBBhL6JCMJ000u5lEeVvXC-8XbYMusq2LujeMGPVdlGPT9W5zTA6sWXk82e0ReZ1NX_K7eP58e59P5nHJQXRxxQ1ya4xNU1qkBWPKSlaIcBOZgEKizSpmMsXBVgylRayYLZSUqVRJWRo-IuNt7tq17z36Toe_SlytTINt7zXNMgkCOIVAz__QZdu7Jnz3pVQqZChjRC63qnSt9w6tXrtFbdxGU9CfDerfDQZ-tgvtixqrH_xdWQAXW1DXXje4rP_P-QArInNl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1887965753</pqid></control><display><type>article</type><title>An FDA Commissioner for the 21st Century</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Chandra, Amitabh ; Sachs, Rachel E</creator><creatorcontrib>Chandra, Amitabh ; Sachs, Rachel E</creatorcontrib><description>The FDA faces challenges including a speed-versus-safety trade-off, the need to work well with industry, pressure on drug pricing, and tough policy choices under the 21st Century Cures Act. Commissioner-nominee Scott Gottlieb seems well qualified to address them.
President Donald Trump has named Scott Gottlieb as his nominee to be the next commissioner of the Food and Drug Administration (FDA). As compared with some of the other people whose names were floated publicly for the position, Gottlieb is a traditional choice, a physician who served in a deputy commissioner role under President George W. Bush. Observers who opposed Commissioner Robert Califf because of his relationships with drug companies will surely express concern about Gottlieb’s consulting in this area. But he would have been on the short list for any Republican administration. If confirmed, Gottlieb would take the helm . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMp1703979</identifier><identifier>PMID: 28402241</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Alzheimer's disease ; Biomarkers ; Bush, George W ; Drug Approval - organization & administration ; Drug Costs ; Drug Industry ; Drugs ; FDA approval ; Federal regulation ; Gottlieb ; Gottlieb, Scott ; History, 21st Century ; Pharmaceutical industry ; Time Factors ; Trump, Donald J ; United States ; United States Food and Drug Administration - organization & administration</subject><ispartof>The New England journal of medicine, 2017-04, Vol.376 (15), p.e31-e30</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright Massachusetts Medical Society Apr 13, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-d3ae3faaf661b6b229f72b53055850b7ef8d2a8930fd2e7feed2fb9776794cca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMp1703979$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1887965753?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28402241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chandra, Amitabh</creatorcontrib><creatorcontrib>Sachs, Rachel E</creatorcontrib><title>An FDA Commissioner for the 21st Century</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The FDA faces challenges including a speed-versus-safety trade-off, the need to work well with industry, pressure on drug pricing, and tough policy choices under the 21st Century Cures Act. Commissioner-nominee Scott Gottlieb seems well qualified to address them.
President Donald Trump has named Scott Gottlieb as his nominee to be the next commissioner of the Food and Drug Administration (FDA). As compared with some of the other people whose names were floated publicly for the position, Gottlieb is a traditional choice, a physician who served in a deputy commissioner role under President George W. Bush. Observers who opposed Commissioner Robert Califf because of his relationships with drug companies will surely express concern about Gottlieb’s consulting in this area. But he would have been on the short list for any Republican administration. If confirmed, Gottlieb would take the helm . . .</description><subject>Alzheimer's disease</subject><subject>Biomarkers</subject><subject>Bush, George W</subject><subject>Drug Approval - organization & administration</subject><subject>Drug Costs</subject><subject>Drug Industry</subject><subject>Drugs</subject><subject>FDA approval</subject><subject>Federal regulation</subject><subject>Gottlieb</subject><subject>Gottlieb, Scott</subject><subject>History, 21st Century</subject><subject>Pharmaceutical industry</subject><subject>Time Factors</subject><subject>Trump, Donald J</subject><subject>United States</subject><subject>United States Food and Drug Administration - organization & administration</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0D1PwzAQBmALgWgpbMwoEgwdCJztOI7HKrR8qMACs-UkZ9GqSYqdDP33GFoQQtxywz16dXoJOaVwRUGk10_Th8c1lcCVVHtkSAXncZJAuk-GACyLE6n4gBx5v4QwNFGHZMCyBBhL6JCMJ000u5lEeVvXC-8XbYMusq2LujeMGPVdlGPT9W5zTA6sWXk82e0ReZ1NX_K7eP58e59P5nHJQXRxxQ1ya4xNU1qkBWPKSlaIcBOZgEKizSpmMsXBVgylRayYLZSUqVRJWRo-IuNt7tq17z36Toe_SlytTINt7zXNMgkCOIVAz__QZdu7Jnz3pVQqZChjRC63qnSt9w6tXrtFbdxGU9CfDerfDQZ-tgvtixqrH_xdWQAXW1DXXje4rP_P-QArInNl</recordid><startdate>20170413</startdate><enddate>20170413</enddate><creator>Chandra, Amitabh</creator><creator>Sachs, Rachel E</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170413</creationdate><title>An FDA Commissioner for the 21st Century</title><author>Chandra, Amitabh ; Sachs, Rachel E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-d3ae3faaf661b6b229f72b53055850b7ef8d2a8930fd2e7feed2fb9776794cca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer's disease</topic><topic>Biomarkers</topic><topic>Bush, George W</topic><topic>Drug Approval - organization & administration</topic><topic>Drug Costs</topic><topic>Drug Industry</topic><topic>Drugs</topic><topic>FDA approval</topic><topic>Federal regulation</topic><topic>Gottlieb</topic><topic>Gottlieb, Scott</topic><topic>History, 21st Century</topic><topic>Pharmaceutical industry</topic><topic>Time Factors</topic><topic>Trump, Donald J</topic><topic>United States</topic><topic>United States Food and Drug Administration - organization & administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chandra, Amitabh</creatorcontrib><creatorcontrib>Sachs, Rachel E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chandra, Amitabh</au><au>Sachs, Rachel E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An FDA Commissioner for the 21st Century</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2017-04-13</date><risdate>2017</risdate><volume>376</volume><issue>15</issue><spage>e31</spage><epage>e30</epage><pages>e31-e30</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The FDA faces challenges including a speed-versus-safety trade-off, the need to work well with industry, pressure on drug pricing, and tough policy choices under the 21st Century Cures Act. Commissioner-nominee Scott Gottlieb seems well qualified to address them.
President Donald Trump has named Scott Gottlieb as his nominee to be the next commissioner of the Food and Drug Administration (FDA). As compared with some of the other people whose names were floated publicly for the position, Gottlieb is a traditional choice, a physician who served in a deputy commissioner role under President George W. Bush. Observers who opposed Commissioner Robert Califf because of his relationships with drug companies will surely express concern about Gottlieb’s consulting in this area. But he would have been on the short list for any Republican administration. If confirmed, Gottlieb would take the helm . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28402241</pmid><doi>10.1056/NEJMp1703979</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2017-04, Vol.376 (15), p.e31-e30 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1887050310 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Alzheimer's disease Biomarkers Bush, George W Drug Approval - organization & administration Drug Costs Drug Industry Drugs FDA approval Federal regulation Gottlieb Gottlieb, Scott History, 21st Century Pharmaceutical industry Time Factors Trump, Donald J United States United States Food and Drug Administration - organization & administration |
| title | An FDA Commissioner for the 21st Century |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20FDA%20Commissioner%20for%20the%2021st%20Century&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Chandra,%20Amitabh&rft.date=2017-04-13&rft.volume=376&rft.issue=15&rft.spage=e31&rft.epage=e30&rft.pages=e31-e30&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMp1703979&rft_dat=%3Cproquest_cross%3E4321693071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1887965753&rft_id=info:pmid/28402241&rfr_iscdi=true |